In other words, adaptive immune resistance, known as the type I tumor microenvironment, may have the benefit of anti-PD-L1 therapy to disable the effects of PD-L1, which suppresses the antitumoral activity of CD8 T cells38. This evidence concerns the gene CD8A and neoplasm.